EP1056774A1 - Derives de glp-1 tronques a l'extremite n-terminale - Google Patents

Derives de glp-1 tronques a l'extremite n-terminale

Info

Publication number
EP1056774A1
EP1056774A1 EP99906075A EP99906075A EP1056774A1 EP 1056774 A1 EP1056774 A1 EP 1056774A1 EP 99906075 A EP99906075 A EP 99906075A EP 99906075 A EP99906075 A EP 99906075A EP 1056774 A1 EP1056774 A1 EP 1056774A1
Authority
EP
European Patent Office
Prior art keywords
glp
xaa
lys
derivative
asp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99906075A
Other languages
German (de)
English (en)
Inventor
Liselotte Bjerre Knudsen
Per Olaf Huusfeldt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of EP1056774A1 publication Critical patent/EP1056774A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Definitions

  • the present invention relates to novel derivatives of human glucagon-like peptide-1 (GLP-1) and fragments analogues thereof having a protracted profile of action and to the use of such derivatives in pharmaceutical compositions.
  • GLP-1 human glucagon-like peptide-1
  • GLP-1 (Glucacon-Like-Peptide-1) is an important gut hormone with regulatory function in glucose metabolism and gastrointestinal secretion and metabolism.
  • Human GLP-1 is a 37 amino acid residue peptide originating from preproglucagon which is synthesised la. in the L-cells in the distal ileum, in the pancreas and in the brain. Processing of preproglucagon to give GLP-1 (7- 36)amide, GLP-1 (7-37) and GLP-2 occurs mainly in the L-cells.
  • WO 87/06941 disclose peptide fragments which comprises GLP-1 (7-37) and functional derivatives thereof and to its use as an insulinotropic agent.
  • WO 90/11296 disclose peptide fragments which comprise GLP-1 (7-36) and functional derivatives thereof and have an insulinotropic activity which exceeds the insulinotropic activity of GLP-1 (1-36) or GLP-1 (1-37) and to their use as insulinotropic agents.
  • GLP-1 (7-36)amide and GLP-1 (7-37) is: 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-
  • WO 91/11457 discloses analogues of the active GLP-1 peptides 7-34, 7- 35, 7-36, and 7-37.
  • WO 98/08871 discloses GLP-1 derivatives in which a lipophilic substituent is attached to at least one amino acid residue.
  • the lipophilic substituents are in particular long-chain groups containing e.g. 12-24 carbon atoms.
  • EP 0699686-A2 (Eli Lilly & Co.) discloses certain N-terminal truncated fragments of GLP- 1 that are reported to be biologically active.
  • the present invention relates to derivatives of GLP-1 and analogues thereof.
  • the derivatives according to the invention have interesting pharmacological properties, including a protracted profile of action.
  • the derivatives also are more metabolically and physically stable, and more soluble.
  • the GLP-1 derivatives and analogues of the present invention are truncated at the N- terminal end and comprise a lipophilic substituent (optionally via a spacer) attached to at least one amino acid residue.
  • the lipophilic substituent is in particular a long-chain group of the type described in WO 98/08871 (Novo Nordisk A/S).
  • the invention relates to an N-terminal truncated GLP-1 derivative comprising a parent peptide of formula II
  • A is a peptide comprising the amino acid residues of GLP-1 (8-18) or a fragment thereof;
  • B is an integer in the range of 35-45;
  • X is -OH, -NH 2 , or a C 1-6 alkyl amide or C 1-6 dialkyl amide group; or an analogue thereof; and wherein a lipophilic substituent is attached to at least one amino acid residue.
  • Gly 8 -GLP-1 (7-37) designates a fragment which relates to GLP-1 (1-37) by the deletion of the amino acid residues at positions 1 to 6 and the substitution of the naturally occurring amino acid residue in position 8 (Ala) with Gly.
  • Lys 3 (N ⁇ -tetradecanoyl)-GLP-1 (7-37) designates GLP-1 (7-37) wherein the ⁇ -amino group of the Lys residue in position 34 has been tetradecanoylated.
  • the amino acid residue in position 38 is Arg unless otherwise indicated
  • the amino acid residue in position 39 is also Arg unless otherwise indicated
  • the amino acid residue in position 40 is Asp unless otherwise indicated.
  • the amino acid sequence of this extension is as in the corresponding sequence in human preproglucagon unless otherwise indicated.
  • the present invention relates to derivatives of native GLP-1 and derivatives of GLP-1 analogs.
  • the derivatives are derivatives of native GLP-1 (8-45) or a fragment thereof.
  • the derivatives are derivatives of native GLP-
  • the derivatives are derivatives of native GLP-
  • the derivatives are derivatives of native GLP-
  • A is a peptide selected from the group consisting of GLP-1 (8-18), GLP-1 (9-18), GLP-1 (10-18), GLP-1 (11-18),
  • GLP-1 (18).
  • A is GLP-1 (8-18), GLP-1 (9-18), GLP-1 (10-18), GLP-1 (11 -18) or GLP-
  • A is GLP-1 (8-18).
  • B is 35, 36, 37, 38, 39, 40, 41 , 42, 43 or 44. In a more preferred embodiment, B is 36. In another more preferred embodiment. B is 37. In another more preferred embodiment, B is 38.
  • the present invention also relates to derivatives of analogs of GLP-1.
  • analogue is defined herein as a peptide which relates to a parent peptide by the substitution of one or more amino acid residues of the parent peptide with other amino acid residue(s).
  • up to fifteen, preferably up to ten amino acid residues may be exchanged with any ⁇ -amino acid residue, in particular with any ⁇ -amino acid residue which can be coded for by the genetic code.
  • Preferred analogues are those in which up to six amino acid residues have been exchanged with any ⁇ -amino acid residue which can be coded for by the genetic code.
  • GLP-1 derivatives or analogues are those in which: i) A is selected from the group consisting of GLP-1 (8-18), GLP-1 (9-18) and GLP-1 (10-18); and ii) B is 36, and the parent peptide comprises one or more amino acid substitutions selected from the group consisting of Arg 26 , Arg 34 and Lys 36 ;
  • the parent peptide comprises one or more amino acid substitutions selected from the group consisting of Arg 26 , Arg 34 , Lys 36 and Lys 37 ; or
  • parent peptide B is 38, and the parent peptide comprises one or more amino acid substitutions selected from the group consisting of Arg 26 , Arg 34 , Lys 36 and Lys 38 . ln a further preferred embodiment, a parent peptide for a derivative of the invention is
  • a parent peptide for a derivative of the invention is:
  • the present invention relates to a GLP-1 derivative wherein the parent peptide is selected from the group comprising Arg 26 -GLP-1( ⁇ -37), Arg ⁇ -GLP-
  • the present invention relates to a GLP-1 derivative wherein the parent peptide is selected from the group comprising Arg 26 Lys 38 -GLP-1(8-3 ⁇ ), Arg 2634 Lys 38 -GLP-1( ⁇ -38), Gly 8 Arg 26 Lys 38 -GLP-1 (8-38) and
  • the present invention relates to a GLP-1 derivative wherein the parent peptide is selected from the group comprising Arg 26 Lys 39 -GLP-1(8-39),
  • the present invention relates to a GLP-1 derivative wherein the parent peptide is selected from the group comprising Arg ⁇ Lys ⁇ -GLP- ⁇ - ⁇ O), Arg ⁇ Lys ⁇ -GLP-l (8-40), Gly' ⁇ rg ⁇ Lys ⁇ -GLP-l (8-40) and Gly 8 Arg 26 ' 34 Lys 36 ' 40 -GLP-1 (8-40).
  • the present invention relates to a GLP-1 derivative wherein the parent peptide is:
  • Gly ⁇ rg ⁇ -GLP-I (8-36); Gly ⁇ Arg a ⁇ - 34 Lys 3 ⁇ -GLP-1 (8-36);
  • Gly ⁇ rg ⁇ -GLP-I (8-37); Gly 8 Arg 2634 Lys 36 -GLP-1 ( ⁇ -37);
  • GI Arg ⁇ -GLP-l (8-39); Gly' ⁇ rg ⁇ Lys ⁇ -GLP-l (8-39); Val 8 Arg 26 -GLP-1 (8-36); VaPArg ⁇ -GLP-l (8-36);
  • Val 8 Arg 26 -GLP-1 ( ⁇ -37); Val 8 Arg M -GLP-1 (6-37);
  • GLP-1 ( ⁇ -39); Val ⁇ Asp 35 Arg 2W4 Lys 3 ⁇ -GLP-1 ( ⁇ -36); Val ⁇ Asp M Arg 2W Lys 3 ⁇ -GLP-1 ( ⁇ -36)amide;
  • GLP-1 ( ⁇ -36); Ser ⁇ Glu 35 Arg 2W4 Lys 3 ⁇ -GLP-1 ( ⁇ -36)amide; Ser 8 Glu 36 Arg aw4 Lys 37 GLP-1 ( ⁇ -37);
  • GLP-1 ( ⁇ -36); S ⁇ r ⁇ Asp 35 Arg ⁇ - 3 Lys 3 ⁇ -GLP-1 (8-36)amide; Se Asp ⁇ Arg ⁇ Lys ⁇ GLP-l (8-37); Ser ⁇ Asp 37 Arg aw Lys 3B GLP-1 (8-38); Ser' ⁇ sp ⁇ Arg ⁇ Lys ⁇ -GLP-l (8-39); Sei ⁇ Asp ⁇ Arg ⁇ Lys 36 -
  • GLP-1 (8-36); Ser ⁇ Asp 35 Arg 2W4 Lys 3 ⁇ -GLP-1 (8-36)amide; Ser s Asp 36 Arg 26 ' 34 Lys 37 GLP-1 ( ⁇ -37);
  • Ser' ⁇ sp ⁇ Arg ⁇ Lys ⁇ GLP-l (8-38); Ser 8 Asp 3 ⁇ A ⁇ g a ⁇ - 34 Lys 3 ⁇ -GLP-1 (8-39); Thr 8 Glu 35 Arg 26 ' 34 Lys 36 -
  • GLP-1 (8-36); Tht*Glu 36 Arg 2W4 Lys 3e -GLP-1 ( ⁇ -36)amide; T r ⁇ Glu 3 ⁇ Arg 2 ⁇ - 34 Lys 37 GLP-1 ( ⁇ -37);
  • GLP-1 (8-36); Gly 8 Asp 35 Arg 2634 Lys 36 -GLP-1 (8-36)amide; ( ⁇ -37);
  • GLP-1 (8-36); GI Asp ⁇ Arg ⁇ Lys ⁇ -GLP-l (8-36)amide; Gly 8 Asp 36 Arg 2634 Lys 37 GLP-1 (8-37); (8-36);
  • GLP-1 (8-36)amide
  • Gly' ⁇ sp ⁇ Arg ⁇ Lys ⁇ -GLP-l (8-36)amide
  • GI Asp ⁇ Arg ⁇ Lys ⁇ GLP-l (8-37);
  • Gly' ⁇ sp ⁇ Arg ⁇ Lys GLP-l ( ⁇ -37); Gly 8 Asp 2 Arg 2634 Lys 23 GLP-1 (8-38); Gly' ⁇ sp Arg ⁇ Lys ⁇ GLP-
  • Gly' ⁇ sp Arg ⁇ Lys ⁇ GLP-l ( ⁇ -37); Gly ⁇ Asp 2 ⁇ Arg 2 ⁇ - 34 Lys 27 GLP-1 (8-38); GI Asp ⁇ Arg ⁇ Lys ⁇ GLP-
  • Va Asp ⁇ Arg ⁇ Lys ⁇ GLP-l ( ⁇ -37); VaPAsp ⁇ Arg ⁇ Lys ⁇ GLP-l ( ⁇ -38); VaPAsp Arg ⁇ Lys ⁇ GLP- 1(8-38);
  • VaPAsp ⁇ Arg ⁇ Lys ⁇ GLP-l (8-37); Val 8 Asp 28 Arg 26 ' 34 Lys 27 GLP-1 (8-38); Val ⁇ Asp a ⁇ Arg 2 ⁇ - 34 Lys 27 GLP- 1(8-36);
  • the present invention relates to a GLP-1 derivative wherein the parent peptide is:
  • Val 8 Arg 26 Lys 36 -GLP-1 (8-36); Va ⁇ Arg ⁇ Lys -GLP-l (7-36); Val 8 Arg 26 Lys 36 -GLP-1 (8-37);
  • VafArg ⁇ Lys ⁇ -GLP-l (8-37); Val 8 Arg 26 Lys 37 -GLP-1 (8-37); VafArg ⁇ Lys ⁇ -GLP-l (8-37);
  • VaPArg ⁇ Lys GLP-l (8-37); Val 8 Arg 6 Lys 23 GLP-1 (8-38); Va Arg ⁇ Lys GLP-l (8-36); Val 8 Arg 26 Lys 23 GLP-1 (8-39); Va Arg ⁇ Lys GLP-l (8-39);
  • the present invention relates to derivatives of GLP-1 analogues of formula III:
  • Xaa at position 8 is Ala, Gly, Ser, Thr, Leu, He, Val, Glu, Asp, or Lys, or is deleted
  • Xaa at position 9 is Glu, Asp, or Lys, or is deleted
  • Xaa at positi on 11 is Thr, Ala, Gly, Ser, Leu, He, Val, Glu, Asp, or Lys, or is deleted,
  • Xaa at positi on 22 s Gly, Ala, Ser, Thr, Leu, He, Val, Glu, Asp, or Lys,
  • Xaa at position 42 is Pro, Lys, Glu, or Asp, or is deleted
  • Xaa at position 43 is Glu, Asp, or Lys, or is deleted,
  • Xaa at position 44 is Glu, Asp, or Lys, or is deleted, and
  • Xaa at position 45 is Val, Glu, Asp, or Lys, or is deleted, or (a) a C-1-6-ester thereof, (b) an amide, C-1-6-alkylamide, or C-1-6-dialkylamide thereof and/or (c) a pharmaceutically acceptable salt thereof, wherein
  • a lipophilic substituent is attached optionally via a spacer to one or more of (a) the amino group of the N-terminal amino acid, (b) the carboxy group of the C-terminal amino acid, (c) the ⁇ -amino group of Lys, and/or (d) the carboxy group which is part of the R group of Asp or Glu, and
  • the total number of different amino acids between the derivative of the GLP-1 analog and the corresponding native form of GLP-1 is one, two, three, four, five or six.
  • the total number of different amino acids between the derivative of the GLP-1 analog and the corresponding native form of GLP-1 does not exceed six.
  • the number of different amino acids is five. More preferably, the number of different amino acids is four. Even more preferably, the number of different amino acids is three. Even more preferably, the number of different amino acids is two. Most preferably, the number of different amino acids is one. In order to determine the number of different amino acids, one should compare the amino acid sequence of the derivative of the GLP-1 analog of the present invention with the corresponding native GLP-1.
  • the derivative Gly 8 Arg 26 Lys 34 (N ⁇ -(7-deoxycholoyl))-GLP-1 (7-40) and the correspondiing native GLP-1 (i.e., GLP-1 (7-40)).
  • the derivative Lys 26 (N ⁇ -(7-deoxycholoyl))Arg M -GLP-1 (7-40) and the corresponding native GLP-1.
  • the derivatives of the GLP-1 analogs of the present invention preferably have only one or two Lys.
  • the derivatives of the GLP-1 analogs of the present invention have only one Lys.
  • the derivatives of the GLP-1 analogs of the present invention have only one Lys and Glu or Asp is adjacent to Lys.
  • the amino acids at positions 37-45 are absent.
  • the amino acids at positions 38-45 are absent.
  • the amino acids at positions 39-45 are absent.
  • Xaa at position 8 is Ala, Gly, Ser, Thr, or Val.
  • Xaa at position 9 is Glu.
  • Xaa at position 22 s Gly, Glu, Asp, or Lys.
  • Xaa at position 23 s Gin, Glu, Asp, or Lys.
  • Xaa at position 24 s Ala, Glu, Asp, or Lys.
  • Xaa at position 25 s Ala, Glu, Asp, or Lys.
  • Xaa at position 26 s Lys, Glu, Asp, or Arg.
  • Xaa at position 27 s Glu, Asp, or Lys.
  • Xaa at position 30 Ala, Glu, Asp, or Lys.
  • Xaa at position 32 s Leu, Glu, Asp, or Lys.
  • Xaa at position 33 s Val, Glu, Asp, or Lys.
  • Xaa at position 34 s Lys, Arg, Glu, or Asp.
  • Xaa at position 35 s Gly, Glu, Asp, or Lys.
  • Xaa at position 36 s Arg, Lys, Glu, or Asp.
  • Xaa at position 37 is Gly, Glu, Asp, or Lys.
  • Xaa at position 38 is Arg, or Lys, or is deleted.
  • Xaa at position 39 is deleted.
  • Xaa at position 40 is deleted.
  • Xaa at position 41 is deleted.
  • Xaa at position 42 is deleted.
  • Xaa at position 43 is deleted.
  • Xaa at position 44 is deleted.
  • Xaa at position 45 is deleted.
  • Xaa at position 26 is Arg, each of Xaa at positions 37- 5 is deleted, and each of the other Xaa is the amino acid in native GLP-1 (8-36).
  • Xaa at position 26 is Arg, each of Xaa at positions 38- 5 is deleted, and each of the other Xaa is the amino acid in native GLP-1 (8-37).
  • Xaa at position 26 is Arg, each of Xaa at positions 39- 5 is deleted, and each of the other Xaa is the amino acid in native GLP-1 (8-38).
  • Xaa at position 34 is Arg
  • each of Xaa at positions 37- 5 is deleted
  • each of the other Xaa is the amino acid in native GLP-1 (8-36).
  • Xaa at position 34 is Arg
  • each of Xaa at positions 38- 5 is deleted
  • each of the other Xaa is the amino acid in native GLP-1 (8-37).
  • Xaa at position 34 is Arg
  • each of Xaa at positions 39- 45 is deleted
  • each of the other Xaa is the amino acid in native GLP-1 (8-38).
  • Xaa at positions 26 and 34 is Arg
  • Xaa at position 36 is Lys
  • each of Xaa at positions 37-45 is deleted
  • each of the other Xaa is the amino acid in native GLP-1 (8-36).
  • Xaa at positions 26 and 34 is Arg
  • Xaa at position 36 is Lys
  • each of Xaa at positions 38-45 is deleted
  • each of the other Xaa is the amino acid in native GLP-1 (8-37).
  • Xaa at positions 26 and 34 is Arg
  • Xaa at position 36 is Lys
  • each of Xaa at positions 39-45 is deleted
  • each of the other Xaa is the amino acid in native GLP-1 (8-38).
  • Xaa at positions 26 and 34 is Arg
  • Xaa at position 38 is Lys
  • each of Xaa at positions 39-45 is deleted
  • each of the other Xaa is the amino acid in native GLP-1 (8-38).
  • Xaa at position 8 is Thr, Ser, Gly or Val
  • Xaa at position 37 is Glu
  • Xaa at position 36 is Lys
  • each of Xaa at positions 38-45 is deleted
  • each of the other Xaa is the amino acid in native GLP-1 (8-37).
  • Xaa at position 8 is Thr, Ser, Gly or Val
  • Xaa at position 37 is Glu
  • Xaa at position 36 is Lys
  • each of Xaa at positions 39-45 is deleted
  • each of the other Xaa is the amino acid in native GLP-1 (8-36).
  • Xaa at position 8 is Thr, Ser, Gly or Val
  • Xaa at position 37 is Glu
  • Xaa at position 38 is Lys
  • each of Xaa at positions 39-45 is deleted
  • each of the other Xaa is the amino acid in native GLP-1 (8-38).
  • Xaa at position 18, 23 or 27 is Lys
  • Xaa at positions 26 and 34 is Arg
  • each of Xaa at positions 37-45 is deleted, and each of the other Xaa is the amino acid in native GLP-1 (8-36).
  • Xaa at position 18, 23 or 27 is Lys
  • Xaa at positions 26 and 34 is Arg
  • each of Xaa at positions 38-45 is deleted
  • each of the other Xaa is the amino acid in native GLP-1 (8-37).
  • Xaa at position 18, 23 or 27 is Lys
  • Xaa at positions 26 and 34 is Arg
  • each of Xaa at positions 39-45 is deleted, and each of the other Xaa is the amino acid in native GLP-1 (8-38).
  • Xaa at position 8 is Thr, Ser, Gly, or Val
  • Xaa at position 18, 23 or 27 is Lys
  • Xaa at position 26 and 34 is Arg
  • each of Xaa at positions 37-45 is deleted
  • each of the other Xaa is the amino acid in native GLP-1 (8-36).
  • Xaa at position 8 is Thr, Ser, Gly, or Val
  • Xaa at position 18, 23 or 27 is Lys
  • Xaa at position 26 and 34 is Arg
  • each of Xaa at positions 38-45 is deleted, and each of the other Xaa is the amino acid in native GLP-1 (8-37).
  • Xaa at position 8 is Thr, Ser, Gly, or Val
  • Xaa at position 18, 23 or 27 is Lys
  • Xaa at position 26 and 34 is Arg
  • each of Xaa at positions 39-45 is deleted, and each of the other Xaa is the amino acid in native GLP-1 (8-38).
  • the GLP-1 derivative is Arg 34 ,Lys 26 (N ⁇ -( ⁇ -glutamyl(N ⁇ - tetradecanoyl))) GLP-1 (9-37).
  • derivative is defined as a modification of one or more of the amino acid residues of a peptide by chemical means, either with or without an enzyme, e.g. by alkylation, acylation, ester formation or amide formation.
  • the lipophilic substituents attached to the parent GLP peptide preferably comprise 4-40 carbon atoms, more preferably 8-25 carbon atoms, in particular 12 to 24 carbon atoms, and most preferably 12 to 18 carbon atoms.
  • a lipophilic substituent may be attached to an amino group of the parent GLP-1 peptide by means of a carboxyl group of the lipophilic substituent which forms an amide bond with an amino group of the amino acid residue to which it is attached.
  • the GLP-1 derivatives of the present invention have three lipophilic substituents. ln a more preferred embodiment, the GLP-1 derivatives of the present invention have two lipophilic substituents.
  • the GLP-1 derivatives of the present invention have one lipophilic substituent.
  • Each lipophilic substituent can be attached to (a) the free amino group of the N-terminal amino acid, (b) the free carboxy group of the C-terminal amino acid, (c) the ⁇ -amino group of Lys and/or (d) the carboxy group which is part of the R group of Asp or Glu.
  • a lipophilic substituent is attached to only the carboxy group which is part of the R group of Asp or Glu. In a preferred embodiment, a lipophilic substituent is attached to only the free carboxy group of the C-terminal amino acid.
  • a lipophilic substituent is attached to only an ⁇ -amino group of Lys.
  • the lipophilic substituent is attached to the parent GLP-1 peptide by means of a spacer in such a way that a carboxyl group of the spacer forms an amide bond with an amino group of the parent GLP-1 peptide.
  • the spacer is an ⁇ , ⁇ -amino acid.
  • suitable spacers are succinic acid, Lys, Glu or Asp, or a dipeptide such as Gly-Lys.
  • the spacer is succinic acid, one carboxyl group thereof may form an amide bond with an amino group of the amino acid residue, and the other carboxyl group thereof may form an amide bond with an amino group of the lipophilic substituent.
  • the spacer is Lys, Glu or Asp
  • the carboxyl group thereof may form an amide bond with an amino group of the amino acid residue
  • the amino group thereof may form an amide bond with a carboxyl group of the lipophilic substituent.
  • a further spacer may in some instances be inserted between the ⁇ -amino group of Lys and the lipophilic substituent.
  • such a further spacer is succinic acid which forms an amide bond with the ⁇ -amino group of Lys and with an amino group present in the lipophilic substituent.
  • such a further spacer is Glu or Asp which forms an amide bond with the ⁇ -amino group of Lys and another amide bond with a carboxyl group present in the lipophilic substituent.
  • Other preferred spacers are ⁇ -L-glutamyl, ⁇ -L- asparagyl, glycyl, ⁇ -alanyl, and ⁇ -( ⁇ -aminobutanoyl).
  • the lipophilic substituent has a group which can be negatively charged.
  • One preferred group which can be negatively charged is a carboxylic acid group.
  • the lipophilic substituent comprises from 6 to 40 carbon atoms, more preferably from 12 to 25 carbon atoms, and most preferably 12 to 18 carbon atoms.
  • the lipophilic substituent is attached to the parent peptide by means of a spacer which is an unbranched alkane ⁇ , ⁇ -dicarboxylic acid group having from 1 to 7 methylene groups, preferably two methylene groups which spacer forms a bridge between an amino group of the parent peptide and an amino group of the lipophilic substituent.
  • the lipophilic substituent is attached to the parent peptide by means of a spacer which is an amino acid residue except Cys or Met, or a dipeptide such as Gly-Lys.
  • a dipeptide such as Gly-Lys means a dipeptide wherein the C-terminal amino acid residue is Lys, His or Trp, preferably Lys, and wherein the N- terminal amino acid residue is selected from the group comprising Ala, Arg, Asp, Asn, Gly, Glu, Gin, He, Leu, Val, Phe and Pro.
  • the lipophilic substituent is attached to the parent peptide by means of a spacer which is an amino acid residue except Cys or Met, or is a dipeptide such as Gly-Lys, and wherein an amino group of the parent peptide forms an amide bond with a carboxylic group of the amino acid residue or dipeptide spacer, and an amino group of the amino acid residue or dipeptide spacer forms an amide bond with a carboxyl group of the lipophilic substituent.
  • the lipophilic substituent comprises a partially or completely hydrogenated cyclopentanophenathrene skeleton.
  • the lipophilic substituent is a straight-chain or branched alkyl group.
  • the lipophilic substituent is an acyl group of a straight- chain or branched fatty acid, more preferably, an acyl group of a straight-chain fatty acid.
  • the lipophilic substituent is an acyl group selected from the group comprising CH 3 (CH 2 ) n CO-, wherein n is an integer from 4 to 38, preferably an integer from 4 to 24, more preferred selected from the group comprising CH 3 (CH 2 ) 6 CO-, CH 3 (CH 2 ) 8 CO-, CH 3 (CH 2 ) 10 CO-, CH 3 (CH 2 ) 12 CO-, CH 3 (CH 2 ) 14 CO-, CH 3 (CH 2 ) 16 CO-, CH 3 (CH 2 ) 18 CO- , CH 3 (CH 2 ) 20 CO- and CH 3 (CH 2 ) 22 CO-.
  • the lipophilic substituent is tetradecanoyl.
  • the lipophilic substituent is hexadecanoyl.
  • the lipophilic substituent is an acyl group of a straight- chain or branched alkane ⁇ , ⁇ -dicarboxylic acid.
  • the lipophilic substituent is an acyl group selected from the group comprising HOOC(CH 2 ) m CO-, wherein m is an integer from 4 to 38, preferably an integer from 4 to 24, more preferred selected from the group comprising HOOC(CH 2 ) 14 CO-, HOOC(CH 2 ) 16 CO-, HOOC(CH 2 ) 18 CO-, HOOC(CH 2 ) 20 CO- and HOOC(CH 2 ) 22 CO-.
  • the lipophilic substituent with the attached spacer is a group of the formula CH 3 (CH 2 ) p NH-CO(CH 2 ) 2 CO-, wherein p is an integer of from 8 to 33, preferably from 12 to 28.
  • the lipophilic substituent with the attached spacer is a group of the formula CH 3 (CH 2 ) r CO-NHCH(COOH)(CH 2 ) 2 CO-, wherein r is an integer of from 10 to 24.
  • the lipophilic substituent with the attached spacer is a group of the formula CH 3 (CH 2 ) s CO-NHCH((CH 2 ) 2 COOH)CO-, wherein s is an integer of from ⁇ to 24.
  • the lipophilic substituent is a group of the formula COOH(CH 2 ) t CO- wherein t is an integer of from ⁇ to 24.
  • the lipophilic substituent with the attached spacer is a group of the formula -NHCH(COOH)(CH 2 ) 4 NH-CO(CH 2 ) u CH 3 , wherein u is an integer of from ⁇ to 1 ⁇ .
  • the lipophilic substituent with the attached spacer is a group of the formula CH 3 (CH 2 ) v CO-NH-(CH 2 ) 2 -CO, wherein n is an integer of from 8 to 24 and z is an integer of from 1 to 6.
  • the lipophilic substituent with the attached spacer is a group of the formula -NHCH(COOH)(CH 2 ) 4 NH-COCH((CH 2 ) 2 COOH)NH-CO(CH 2 ) w CH 3l wherein w is an integer of from 10 to 16.
  • the lipophilic substituent with the attached spacer is a group of the formula -NHCH(COOH)(CH 2 ) 4 NH-CO(CH 2 ) 2 CH(COOH)NH-CO(CH 2 ) x CH 3 , wherein x is an integer of from 10 to 16.
  • the lipophilic substituent with the attached spacer is a group of the formula -NHCH(COOH)(CH 2 ) 4 NH-CO(CH 2 ) 2 CH(COOH)NHCO(CH 2 ) y CH 3 , wherein y is zero or an integer of from 1 to 22.
  • the lipophilic substituent can be negatively charged.
  • a lipophilic substituent can for example be a substituent which has a carboxyl group.
  • the derivatives of GLP-1 analogues of the present invention may be in the form of one or more of (a) a C-1-6-ester, (b) an amide, C-1-6-alkylamide, or C-1-6-dialkylamide, and (c) a pharmaceutical salt.
  • the derivatives of GLP-1 analogues are in the form of an acid addition salt or a carboxylate salt, most preferably in the form of an acid addition salt.
  • the present invention also relates to pharmaceutical compositions comprising a derivative of a GLP-1 analog of the present invention and a pharmaceutically acceptable vehicle or carrier.
  • the pharmaceutical compositions comprise an isotonic agent, a preservative and a buffer.
  • isotonic agents are sodium chloride, mannitol and glycerol.
  • preservatives are phenol, m-cresol, methyl p-hydroxybenzoate and benzyl alcohol.
  • Suitable buffers include sodium acetate, sodium citrate, glycylglycine, histidine, 2-phenylethanol and sodium phosphate.
  • the pharmaceutical compositions preferably further comprise a surfactant in order to improve the solubility and/or the stability of the GLP-1 derivative.
  • the surfactant is poloxymer 1 ⁇ , tween 20 or tween ⁇ O.
  • the pharmaceutical compositions preferably also comprise zinc.
  • compositions preferably also comprise protamine.
  • the pharmaceutial compositions preferably further comprise another antidiabetic agent.
  • antidiabetic agent includes compounds for the treatment and/or prophylaxis of insulin resistance and diseases wherein insulin resistance is the pathophysiological mechanism.
  • the antidiabetic agent is an insulin, more preferably human insulin.
  • the antidiabetic agent is a hypoglycaemic agent, preferably an oral hypoglycaemic agent.
  • Oral hypoglycaemic agents are preferably selected from the group consisting of sulfonylureas, biguanides, thiazolidinediones, glucosidase inhibitors, glucagon antagonists, GLP-1 agonists, potasium channel openers, insulin sensitizers, hepatic enzyme inhibitors, glucose uptake modulators, compounds modifying the lipid metabolism, compounds lowering food intake, and agents acting on the ATP-dependent potassium channel of the ⁇ -cells.
  • Preferred sulfonylureas are tolbutamide, glibenclamide, glipizide and gliclazide.
  • a preferred biguanide is metformin.
  • Preferred thiazolidinediones are troglitazone and ciglitazone.
  • a preferred glucosidase inhibitor is acarbose.
  • Preferred agents acting on the ATP-dependent potassium channel of the ⁇ -cells are: glibenclamide, glipizide, gliclazide, and repaglinide.
  • the GLP-1 derivative is provided in the form of a composition suitable for administration by injection.
  • a composition can either be an injectable solution ready for use or it can be an amount of a solid composition, e.g. a lyophilised product, which has to be dissolved in a solvent before it can be injected.
  • the injectable solution preferably contains not less than about 2 mg/ml, preferably not less than about 5 mg/ml, more preferred not less than about 10 mg/ml of the GLP-1 derivative and, preferably, not more than about 100 mg/ml of the GLP-1 derivative.
  • the pharmaceutical compositions of the present invention also preferably comprise another anti-obesity drug.
  • the antiobesity agent is leptin. In another embodiment the antiobesity agent is amphetamin. In another embodiment the antiobesity agent is dexfenfluramine. In another embodiment the antiobesity agent is sibutramine.
  • the antiobesity agent is orlistat.
  • the antiobesity agent is selected from a group of CART agonists, NPY antagonists, orexin antagonists, H3-antagonists, TNF agonists, CRF agonists, CRF BP antagonists, urocortin agonists, ⁇ 3 agonists, MSH agonists, CCK agonists, serotonin re-uptake inhibitors, mixed serotonin and noradrenergic compounds, 5HT agonists, bombesin agonists, galanin antagonists, growth hormone, growth hormone releasing compounds, glucagon, TRH agonists, uncoupling protein 2 or 3 modulators, leptin agonists, DA agonists (Bromocriptin, Doprexin), lipase/amyiase inhibitors, PPAR modulators, PXR modulators or TR ⁇ agonists.
  • GLP-1 derivatives of the present invention exist in a partially structured micellar-like aggregated form when added to water or an aqueous solution. This structure makes them more soluble and stable in solution as compared to native GLP-1.
  • the increased solubility and stability can be seen by comparing the solubility after 9 days of standing for a derivative and normal GLP-1 (7-37) in a pharmaceutical formulation, e.g. 5 mM phosphate buffer, pH 6.9 added 0.1 M NaCI.
  • Circular Dichroism (CD) can be used to show that the GLP-1 derivatives have a certain partially structured conformation.
  • the helix content of some GLP-1 derivatives of the present invention increases with increasing concentration, from 10-15% to 30-35% (at a concentration of 500 ⁇ M) in parallel with peptide self-association.
  • the helix content remains constant above 30% at concentrations of 10 ⁇ M.
  • the size of the partially helical, micelle-like aggregates may be estimated by size- exclusion chromatography.
  • the apparent (critical micelle concentrations) CMC's of the peptides may be estimated from the concentration dependent fluorescence in the presence of appropriate dyes (e.g. Brito, R. & Vaz, W. (1966) Anal.
  • the present invention also relates to pharmaceutical compositions comprising water and a GLP-1 derivative of the present invention which has a helix content as measured by Circular Dichroism at 222 nm in H 2 O at 22 ⁇ 2°C exceeding 25%, preferably in the range of 25% to 50%, at a peptide concentration of about 10 ⁇ M.
  • the present invention also relates to the use of a GLP-1 derivative of the present invention for the preparation of a medicament which has a protracted profile of action relative to GLP-1 (7-37).
  • the present invention also relates to the use of a GLP-1 derivative of the present invention for the preparation of a medicament with protracted effect for the treatment of non- insulin dependent diabetes mellitus.
  • the present invention also relates to the use of a GLP-1 derivative of the present invention for the preparation of a medicament with protracted effect for the treatment of insulin dependent diabetes mellitus.
  • the present invention also relates to the use of a GLP-1 derivative of the present invention for treating insulin resistance.
  • the present invention also relates to the use of a GLP-1 derivative of the present invention for the preparation of a medicament with protracted effect for the treatment of obesity.
  • the present invention relates to a method of treating insulin dependent or non-insulin dependent diabetes mellitus in a patient in need of such a treatment, comprising administering to the patient a therapeutically effective amount of a GLP-1 derivative of the present invention together with a pharmaceutically acceptable carrier.
  • the present invention relates to a method of treating obesity in a patient in need of such a treatment, comprising administering to the patient a therapeutically effective amount of a GLP- 1 derivative of the present invention together with a pharmaceutically acceptable carrier.
  • the particular GLP-1 derivative to be used and the optimal dose level for any patient will depend on the disease to be treated and on a variety of factors including the efficacy of the specific peptide derivative employed, the age, body weight, physical activity, and diet of the patient, on a possible combination with other drugs, and on the severity of the case.
  • the pharmaceutical compositions of the present invention may be administered parenterally to patients in need of such a treatment.
  • Parenteral administration may be performed by subcutaneous, intramuscular or intravenous injection by means of a syringe, optionally a penlike syringe.
  • parenteral administration can be performed by means of an infusion pump.
  • a further option is a composition which may be a powder or a liquid for the administration of the GLP-1 derivative in the form of a nasal or pulmonal spray.
  • the GLP-1 derivatives of the invention can also be administered transdermally, e.g. from a patch, optionally a iontophoretic patch, or transmucosally, e.g. bucally.
  • the parent peptide can be produced by a method which comprises culturing a host cell containing a DNA sequence encoding the polypeptide and capable of expressing the polypeptide in a suitable nutrient medium under conditions permitting the expression of the peptide, after which the resulting peptide is recovered from the culture.
  • the medium used to culture the cells may be any conventional medium suitable for growing the host cells, such as minimal or complex media containing appropriate supplements. Suitable media are available from commercial suppliers or may be prepared according to published recipes (e.g. in catalogues of the American Type Culture Collection).
  • the peptide produced by the cells may then be recovered from the culture medium by conventional procedures including separating the host cells from the medium by centrifugation or filtration, precipitating the proteinaceous components of the supernatant or filtrate by means of a salt, e.g. ammonium sulphate, purification by a variety of chromatographic procedures, e.g. ion exchange chromatography, gel filtration chromatography, affinity chromatography, or the like, dependent on the type of peptide in question.
  • a salt e.g. ammonium sulphate
  • the DNA sequence encoding the parent peptide may suitably be of genomic or cDNA origin, for instance obtained by preparing a genomic or cDNA library and screening for DNA sequences coding for all or part of the peptide by hybridisation using synthetic oiigonucleotide probes in accordance with standard techniques (see, for example, Sambrook, J, Fritsch, EF and Maniatis, T, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York, 1989).
  • the DNA sequence encoding the peptide may also be prepared synthetically by established standard methods, e.g.
  • the DNA sequence may also be prepared by polymerase chain reaction using specific primers, for instance as described in US 4,683,202 or Saiki et al. , Science 239 (1988), 487 - 491.
  • the DNA sequence may be inserted into any vector which may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced.
  • the vector may be an autonomously replicating vector, i.e.
  • the vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g. a plasmid.
  • the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated.
  • the vector is preferably an expression vector in which the DNA sequence encoding the peptide is operably linked to additional segments required for transcription of the DNA, such as a promoter.
  • the promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell. Examples of suitable promoters for directing the transcription of the DNA encoding the peptide of the invention in a variety of host cells are well known in the art, cf. for instance Sambrook et al., supra.
  • the DNA sequence encoding the peptide may also, if necessary, be operably connected to a suitable terminator, polyadenylation signals, transcriptional enhancer sequences, and translational enhancer sequences.
  • the recombinant vector of the invention may further comprise a DNA sequence enabling the vector to replicate in the host cell in question.
  • the vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell or one which confers resistance to a drug, e.g. ampicillin, kanamycin, tetracyclin, chloramphenicol, neomycin, hygromycin or methotrexate.
  • a selectable marker e.g. a gene the product of which complements a defect in the host cell or one which confers resistance to a drug, e.g. ampicillin, kanamycin, tetracyclin, chloramphenicol, neomycin, hygromycin or methotrexate.
  • a secretory signal sequence (also known as a leader sequence, prepro sequence or pre sequence) may be provided in the recombinant vector.
  • the secretory signal sequence is joined to the DNA sequence encoding the peptide in the correct reading frame.
  • Secretory signal sequences are commonly positioned 5' to the DNA sequence encoding the peptide.
  • the secretory signal sequence may be that normally associated with the peptide or may be from a gene encoding another secreted protein.
  • the host cell into which the DNA sequence or the recombinant vector is introduced may be any cell which is capable of producing the present peptide and includes bacteria, yeast, fungi and higher eukaryotic cells.
  • suitable host cells well known and used in the art are, without limitation, E. coli, Saccharomyces cerevisiae, or mammalian BHK or CHO cell lines.
  • the GLP-1 derivatives and analogues of the present invention may be prepared by methods known perse in the art.
  • the polypeptide portion may be prepared by chemical synthesis using solid phase protein synthesis techniques, or using recombinant DNA techniques, and the GLP-1 peptide having attached thereto a lipophilic substituent may e.g. be prepared as described in PCT/DK97/00340.
  • compositions of the present invention may be prepared by conventional techniques, e.g. as described in Remington's Pharmaceutical Sciences, 1985 or in Remington: The Science and Practice of Pharmacy, 19 th edition, 1995.
  • the injectable compositions of the GLP-1 derivative of the invention can be prepared using the conventional techniques of the pharmaceutical industry which involves dissolving and mixing the ingredients as appropriate to give the desired end product.
  • the GLP-1 derivative is dissolved in an amount of water which is somewhat less than the final volume of the composition to be prepared.
  • An isotonic agent, a preservative and a buffer is added as required and the pH value of the solution is adjusted - if necessary - using an acid, e.g. hydrochloric acid, or a base, e.g. aqueous sodium hydroxide as needed.
  • the volume of the solution is adjusted with water to give the desired concentration of the ingredients.
  • a composition for nasal administration of certain peptides may, for example, be prepared as described in European Patent No. 272097 (Novo Nordisk A/S) or in WO 93/18785.
  • the present invention also relates to methods for producing a GLP-1 derivative of the present invention, comprising alkylating, acylating and/or amidating the corresponding GLP-1 analog.
  • the present invention is further illustrated by the following examples which, however, are not to be construed as limiting the scope of protection. The features disclosed in the foregoing description and in the following examples may, both separately and in any combination thereof, be material for realising the invention in diverse forms thereof.
  • the basic peptide to be modified may comprise amino acid residues 19-35 of GLP-1 as well as one or more additional desired N-terminal and/or C-terminal residues.
  • the basic peptide may thus, by way of example, have amino acid residue 8, 9, 10, 11 or 12 of GLP-1 at its N-terminal end and amino acid residue 36, 37 or 38 of GLP-1 at its C- terminal end.
  • the peptide may of course also contain other modifications as described above.
  • Pal-ONSu Hexadecanoic acid 2,5-dioxopyrrolidin-1-yl ester.
  • Myr-Glu(ONSu)-OBu t N ⁇ -Tetradecanoyl-L-glutamic acid ⁇ -t-butyl ester ⁇ -2,5- dioxopyrrolidin-1-yl ester
  • N ⁇ -Pal- ⁇ -Glu(ONSu)-OBu l N ⁇ -Hexadecanoyl-(L)-glutamic acid ⁇ -t-butyl- ⁇ -2,5- dioxopyrrolidin-1-yl diester.
  • N ⁇ -Ste- ⁇ -Glu(ONSu)-OBu t N ⁇ -Octadecanoyl-(L)-glutamic acid ⁇ -t-butyl- ⁇ -2,5-dioxopyrrolidin-
  • PDMS Plasma Desorption Mass Spectrometry
  • HPLC High Performance Liquid Chromatography amu: atomic mass units
  • the solvent was removed in vacuo, and the residue was purified by column chromatography using a cyanopropyl column (Zorbax 300SB-CN) and a standard acetonitril TFA system.
  • the column was heated to 65°C and the acetonitril gradient is 0-100% for 60 minutes.
  • the resulting solution was washed with 5% aqueous citric acid (2x25 ml). The solvent was removed in vacuo and the residue dissolved in DMF (36 ml). The resulting solution was carefully added to a 10% aqueous solution of citric acid (357 ml) and extracted with ethyl acetate (200 ml) and dried (MgSO 4 ). The solvent was removed in vacuo to give the crude glutamic diester intermediate.
  • the reaction was quenched by the addition of a solution of glycine (11.6 mg, 155 ⁇ mol) in water (116 ⁇ l). A 0.5% aqueous solution of ammonium acetate (67 ml) was added, and the resulting mixture eluted onto a Varian 5g C8 Mega Bond Elut ® , the immobilised compound washed with 5% aqueous acetonitril (25 ml), and finally liberated from the cartridge by elution with TFA (25 ml). The eluate was concentrated in vacuo, and the residue purified by column chromatography using a cyanopropyl column

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cette invention se rapporte à des dérivés du peptide de type glucagon 1 (GLP-1) tronqués à l'extrémité N-terminale ainsi qu'à des analogues de ces dérivés, qui possèdent un profil d'action prolongée, et à l'utilisation de ces dérivés dans des compositions pharmaceutiques pour le traitement de l'obésité et du diabète sucré insulino-dépendant ou non insulino-dépendant. Ces dérivés de GLP-1 possèdent un substituant lipophile fixé à au moins un résidu d'acide aminé.
EP99906075A 1998-02-27 1999-02-25 Derives de glp-1 tronques a l'extremite n-terminale Withdrawn EP1056774A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DK26498 1998-02-27
DK26498 1998-02-27
DK50998 1998-04-08
DK50998 1998-04-08
PCT/DK1999/000081 WO1999043705A1 (fr) 1998-02-27 1999-02-25 Derives de glp-1 tronques a l'extremite n-terminale

Publications (1)

Publication Number Publication Date
EP1056774A1 true EP1056774A1 (fr) 2000-12-06

Family

ID=26063639

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99906075A Withdrawn EP1056774A1 (fr) 1998-02-27 1999-02-25 Derives de glp-1 tronques a l'extremite n-terminale

Country Status (4)

Country Link
EP (1) EP1056774A1 (fr)
JP (1) JP2002508162A (fr)
AU (1) AU2610599A (fr)
WO (1) WO1999043705A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9615829B2 (en) 2008-09-23 2017-04-11 Covidien Lp Tissue stop for surgical instrument

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002523333A (ja) 1998-07-31 2002-07-30 ノボ ノルディスク アクティーゼルスカブ Ｉｉ型糖尿病を予防するためのｇｌｐ−１及び類似体の利用
EP1105460B1 (fr) 1998-08-10 2009-10-07 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Differenciation des cellules ne produisant pas d'insuline -ellules produisant de l'insuline, differenciees de cellules ne produisant pas d'insuline, au moyen de glp-1 ou d'exendine-4 et leurs utilisations
CZ295044B6 (cs) 1998-12-07 2005-05-18 Societe De Conseils De Recherches Et D'application Analogy GLP-1, mající kyselinu aminoizomáselnou na pozicích 8 a 35, jejich použití a farmaceutické prostředky je obsahující
EP1992641A3 (fr) 1998-12-07 2009-07-29 Ipsen Pharma Analogues GLP-1
EP1196189A2 (fr) 1999-06-25 2002-04-17 Medtronic MiniMed, Inc. Therapie anti diabete a agents multiples
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
US6569901B2 (en) * 2000-01-28 2003-05-27 Novo Nordisk A/S Alkynyl-substituted propionic acid derivatives, their preparation and use
EP1263458B1 (fr) 2000-03-08 2005-11-16 Novo Nordisk A/S Reduction du cholesterol seriques
ATE416784T1 (de) 2000-12-01 2008-12-15 Takeda Pharmaceutical Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
AU2002248464A1 (en) 2001-02-21 2002-09-12 Medtronic Minimed, Inc. Stabilized insulin formulations
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
CN1363654A (zh) 2001-07-19 2002-08-14 上海华谊生物技术有限公司 生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法
AU2002317599B2 (en) 2001-07-31 2008-04-03 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GLP-1 exendin-4 peptide analogs and uses thereof
CA2452044A1 (fr) * 2001-08-28 2003-03-13 Eli Lilly And Company Pre-melanges de polypeptide glp-1 et d'insuline basale
JP2005508360A (ja) * 2001-10-19 2005-03-31 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１およびインスリンの二相混合物
PT1463751E (pt) * 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
KR20060013369A (ko) 2003-03-28 2006-02-09 독립행정법인농업생물자원연구소 재조합 단백질이 다량 생산되는 식물 저장 기관의 생산방법 및 신규 재조합 단백질
CN102174102A (zh) 2003-05-15 2011-09-07 塔夫茨大学信托人 肽和多肽药物的稳定类似物
TW200526254A (en) * 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
TW200522976A (en) 2003-09-19 2005-07-16 Novo Nordisk As Novel plasma protein affinity tags
RU2421238C2 (ru) 2003-11-20 2011-06-20 Ново Нордиск А/С Пептидная композиция, содержащая пропиленгликоль, являющаяся оптимальной для изготовления и применения в инъекционных устройствах
EP1694356B1 (fr) 2003-12-09 2011-02-16 Novo Nordisk A/S Regulation d'une preference alimentaire au moyen d'agonistes de glp-1
EP1694278A4 (fr) 2003-12-16 2009-08-12 Ipsen Pharma Compositions pharmaceutiques glp-1
EP1711523B1 (fr) 2003-12-16 2012-10-10 Ipsen Pharma Analogues du glp-1
JP2007537149A (ja) 2004-01-08 2007-12-20 セラテクノロジーズ インコーポレイテッド 長時間作用性のグルカゴン様ペプチド−１類似体
EP1758575A1 (fr) 2004-06-11 2007-03-07 Novo Nordisk A/S Remede contre l'obesite induite par les medicaments au moyen d'agonistes glp-1
DE102004043153B4 (de) * 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
RU2007134155A (ru) 2005-03-18 2009-04-27 Ново Нордиск А/С (DK) Glp-1 соединения с увеличенным временем полужизни
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
WO2006097535A2 (fr) * 2005-03-18 2006-09-21 Novo Nordisk A/S Agonistes de peptides de la famille du glucagone presentant une activite similaire a la secretine
UA90718C2 (ru) 2005-05-10 2010-05-25 Лаборатуар Фурнье С.А. Новое применение агонистов печеночного рецептора х
CA2617859A1 (fr) 2005-06-30 2007-01-11 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Compositions pharmaceutiques de glp-1
WO2007055743A2 (fr) * 2005-11-01 2007-05-18 Amylin Pharmaceuticals, Inc. Procédés pour traiter l'obésité et des troubles associés
JP2010043001A (ja) * 2006-11-09 2010-02-25 Sanwa Kagaku Kenkyusho Co Ltd Ｇｌｐ−１誘導体とその用途
KR20110039348A (ko) 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
US8889618B2 (en) 2008-11-07 2014-11-18 The General Hospital Corporation C-terminal fragments of glucagon-like peptide-1 (GLP-1)
US8513192B2 (en) 2009-01-22 2013-08-20 Novo Nordisk A/S Stable growth hormone compounds resistant to proteolytic degradation
CN101987868B (zh) 2009-07-30 2013-09-04 江苏豪森医药集团有限公司 Glp-1类似物的衍生物或其可药用盐和用途
CN105963710A (zh) 2009-08-06 2016-09-28 诺沃—诺迪斯克保健股份有限公司 具有延长的体内功效的生长激素
WO2011073328A1 (fr) 2009-12-16 2011-06-23 Novo Nordisk A/S Composés agonistes du récepteur glp‑1 avec une extrémité n‑terminale modifiée
CN103002918B (zh) 2010-01-22 2016-05-04 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
RU2012134974A (ru) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг Стабилизированное соединение гормона роста
EP2555791B1 (fr) 2010-04-09 2017-11-01 Sinai Health System Méthodes de traitement de troubles du tractus gastro-intestinal au moyen d'un agoniste glp-1
US20130123460A1 (en) 2010-04-30 2013-05-16 Sanwa Kagaku Kenkyusho Co., Ltd. Peptide for improving biostability of bioactive substance, and bioactive substance having improved biostability
WO2012061466A2 (fr) 2010-11-02 2012-05-10 The General Hospital Corporation Méthodes de traitement d'une maladie de stéatose
PL2651398T3 (pl) 2010-12-16 2018-05-30 Novo Nordisk A/S Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
CN103619175B (zh) 2011-04-12 2016-08-17 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
WO2013006692A2 (fr) 2011-07-06 2013-01-10 The General Hospital Corporation Méthodes de traitement utilisant un pentapeptide dérivé de l'extrémité c-terminale du glp-1 (glucagon-like peptide 1)
CN102286092B (zh) 2011-09-14 2014-01-01 深圳翰宇药业股份有限公司 利拉鲁肽的固相合成方法
TR201903918T4 (tr) 2012-03-22 2019-04-22 Novo Nordisk As Bir dağıtım ajanı içeren bileşimler ve bunların hazırlanması.
HRP20231060T1 (hr) 2012-03-22 2023-12-22 Novo Nordisk A/S Pripravci peptida glp-1 i njihova priprava
CN104487056A (zh) 2012-06-20 2015-04-01 诺和诺德A/S（股份有限公司） 包含肽和递送剂的片剂制剂
JP6224586B2 (ja) 2012-07-10 2017-11-01 武田薬品工業株式会社 注射用製剤
EP2981282B1 (fr) 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Formulation d'un composé d'hormone de croissance
CN103980358B (zh) * 2014-01-03 2016-08-31 杭州阿诺生物医药科技股份有限公司 一种制备利拉鲁肽的方法
PE20211202A1 (es) 2017-08-24 2021-07-05 Novo Nordisk As Composiciones de glp-1 y sus usos
EP3746111B1 (fr) 2018-02-02 2023-07-19 Novo Nordisk A/S Compositions solides comportant un agoniste glp-1, du sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylate et un lubrifiant
EP3774862B1 (fr) 2018-04-05 2022-06-08 Sun Pharmaceutical Industries Limited Nouveaux analogues de glp-1
WO2020127476A1 (fr) 2018-12-19 2020-06-25 Krka, D.D., Novo Mesto Composition pharmaceutique comprenant un analogue de glp -1
CN115947849A (zh) 2018-12-21 2023-04-11 江苏恒瑞医药股份有限公司 双特异性蛋白
WO2021123228A1 (fr) 2019-12-18 2021-06-24 Krka, D.D., Novo Mesto Composition pharmaceutique comprenant un analogue de glp-1
WO2021144476A1 (fr) 2020-02-18 2021-07-22 Novo Nordisk A/S Formulations pharmaceutiques
CN115925994B (zh) 2020-09-30 2023-09-22 北京质肽生物医药科技有限公司 多肽缀合物和使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US5574008A (en) * 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5869602A (en) * 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
DK1975177T3 (da) * 1996-03-01 2011-07-25 Novo Nordisk As Appetitundertrykkende peptid, formuleringer dermed og anvendelse deraf
CA2468374C (fr) * 1996-08-30 2010-12-21 Novo-Nordisk A/S Derives de glp-1

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9943705A1 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9615829B2 (en) 2008-09-23 2017-04-11 Covidien Lp Tissue stop for surgical instrument
US10028799B2 (en) 2008-09-23 2018-07-24 Covidien Lp Tissue stop for surgical instrument
US10786324B2 (en) 2008-09-23 2020-09-29 Covidien Lp Tissue stop for surgical instrument

Also Published As

Publication number Publication date
WO1999043705A8 (fr) 1999-10-14
JP2002508162A (ja) 2002-03-19
WO1999043705A1 (fr) 1999-09-02
AU2610599A (en) 1999-09-15

Similar Documents

Publication Publication Date Title
WO1999043705A1 (fr) Derives de glp-1 tronques a l'extremite n-terminale
EP1062240B1 (fr) Derives de glp-1 modifies a l'extremite n-terminale
EP1061946B1 (fr) Derives de glp-1 avec une teneur de structures en helices superieure a 25 %, formant des agregats de type micellaire partiellement structures
CA2264243C (fr) Derives de glp-1
EP3080154B1 (fr) Agonistes doubles du récepteur glp-1/gip
US7226990B2 (en) Extendin derivatives
EP3080150B1 (fr) Analogues peptidiques d'exendine-4 en tant qu'agonistes du récepteur gip/glp-1 double
EP1060191B1 (fr) Derives d'analogues de glp-1
EP2932981B1 (fr) Dérivés du GLP-1 se liant à l'albumine
US6268343B1 (en) Derivatives of GLP-1 analogs
KR20060109940A (ko) 알부민-유사제에 연결된 신규 ｇｌｐ-1 유사체
KR20060135661A (ko) 신규 ｇｌｐ-1 화합물
WO1998008872A1 (fr) Derives de glp-2
JP2001504105A (ja) Ｇｌｐ―１ペプチドの利用
JP2002504527A (ja) 部分的に組織化したミセル様凝集物を形成する２５％を越えるヘリックス成分を有するｇｌｐ−２誘導体
US20080045450A1 (en) GLP-2 Derivatives
AU3847897C1 (en) GLP-1 derivatives
EP1840134B1 (fr) Dérivés du GLP-1
WO2002040537A2 (fr) Analogues et derives du peptide liberateur de gastrine (gpr)
MXPA99001823A (en) Glp-1 derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000927

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HUUSFELDT, PER, OLAF

Inventor name: KNUDSEN, LISELOTTE, BJERRE

17Q First examination report despatched

Effective date: 20030911

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060620